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Abstract
Background: We have earlier shown that Bacille Calmette-Gue ´rin (BCG) vaccine-specific IgG Antibodies in Lymphocyte
Supernatant (ALS) can be used for diagnosis of active tuberculosis (TB) in adults and children.
Methodology/Principal Findings: The ALS method was validated in a larger cohort (n=212) of patients with suspicion of
pulmonary TB using multiple antigens (BCG, LAM, TB15.3, TB51A, CFP10-ESAT6-A, CFP, CW) from Mycobacterium
tuberculosis. The sensitivity and specificity of the ALS assay was calculated using non-TB patients as controls. The sensitivity
and the specificity were highest with BCG vaccine (90% and 88% respectively) followed by LAM (89% and 87% respectively).
Simultaneous assessment of multiple antigen-specific antibodies increased sensitivity (91%) and specificity (88%). Using
higher lymphocyte count in smaller volume of culture media increased detection and reduced the assay duration to
,30 hrs. Twenty one patients with clinical findings strongly suggestive of TB finally diagnosed as non-TB patients were
positive by the ALS assay, of which 9 (43%) were positive for 7 antigens and 19 (90%) for at least 3 antigens.
Conclusions/Significance: Our findings show that simultaneous detection of antigens improves the diagnostic potential of
the ALS assay; the modified method increases sensitivity and can provide results in ,48 hours, and enable detection of
some cases of pulmonary TB that are not detectable by standard methods.
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Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB)
remains a major global public health problem which is responsible
for over 3 million deaths annually. Recent analysis of global
burden of TB revealed that Bangladesh ranks 6
th on the list of 22
highest burden TB countries in the world [1]. These 22 countries
collectively account for 80% of incident TB cases globally. An
efficient TB control program requires early and accurate diagnosis
and treatment of patients with active pulmonary TB. A major
obstacle to early treatment of TB is the lack of rapid accurate
diagnostic methods that can be applied in low-income areas.
Diagnosis of active mycobacterial infections in resource-con-
strained settings is primarily based on clinical examination,
radiological findings, and identification of acid-fast bacilli in
sputum by smear microscopy. Microbiological culture requires
specialized laboratories and is done rarely.
A serological test detecting circulating antibodies against specific
mycobacterial antigens in serum is an attractive approach for the
diagnosis of TB due to its speed and relatively simple technology.
However, serological tests have been hampered by decreased
sensitivity and cross-reactivity with other mycobacteria, and have
relatively limited usefulness in the diagnosis of TB in TB endemic
countries [2,3,4,5]. Additionally, there is great variability in
specific antibody expression in different subjects [6] and antigen
composition of M. tuberculosis bacilli recognized by antibodies also
varies with stages of infection and disease progression [7]. Recent
systematic reviews of commercial serological tests showed that,
commercial tests vary widely in performance [3,8]. The sensitivity
is higher in smear positive than smear-negative samples; specificity
is higher in healthy volunteers than in non-TB suspects where TB
was part of the differential diagnosis [3]. Furthermore, serological
methods have low discriminatory power differentiating latent from
active TB infections in endemic regions [9]. There is a need for
methods to accurately diagnose and discriminate between latent
and active TB infections in endemic regions.
We have previously shown detection of antibody in lymphocyte
supernatants (ALS) is a rapid diagnostic method for the identifi-
cation of patients with active pulmonary TB in adults [10,11] and
in pediatric patients [12] using BCG vaccine as an antigen. Our
aim was to further validate the ALS method in the diagnosis of
pulmonary TB among well-characterized patients with symptom-
atic respiratory diseases and healthy controls, to evaluate TB-
specific antigens other than BCG in the assay, and to explore
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carefully screened and diagnosed according to the standardized
protocol provided by the World Health Organization for TB
Specimen Bank project. Multiple TB antigens were used singly
and in combination for evaluation in the ALS assay.
Results
Characteristics of study participants
Two hundred and twelve patients (median of age, 25 years;
range, 18 to 70 years) with suspected pulmonary TB were
recruited from the NIDCH. The demographical characteristics
are given in Table 1. Patients, especially those who were smear
negative, culture negative and treated for TB based on clinical and
radiographic evaluation (category 3, n=9) and those who were
smear negative, culture negative and were not treated for TB
(category 4 and 9) were followed for 8–12 weeks. The day of
enrollment was considered day 1. Among the category 3 TB index
cases, 6 were lost to follow-up at the 2-month time point. These
patients were being treated with anti-TB therapy and assessment
of clinical and radiological improvement for confirming TB
disease at 2 months follow-up could not be ascertained, although
improvement was noticed at the 1 month follow-up. Four isolates
were identified as nontuberculous Mycobacterium (NTM) though no
species identification was done in the study. For calculation of
sensitivity and specificity of the ALS method, category-3 (n=9)
group was not included since TB disease in this group was
confirmed by an indirect method only i.e. response to anti-TB
therapy where 6 were lost to follow-up. Among the category 9
patients most cases were later diagnosed to have bronchiectasis,
chronic obstructive pulmonary diseases, bronchitis, lung cancer
and lung abscess. About 30 patients remain indeterminate.
All TB patients received the standard treatment by directly
observed treatment short course (DOTS). BCG vaccination status
was confirmed by obtaining medical history from each patient and
inspection of visible scars that typically forms after vaccination
with M. bovis BCG. None of the patients were positive for HIV
infection. A total of twenty five healthy controls (median of age 26
years; range, 22 to 50 years) were enrolled in the study. Eight out of
twenty five healthy subjects had MT a skin induration $10 mm.
The micro-ALS method using higher PBMC
concentrations gives higher BCG-specific IgG responses
in shorter time
Culture supernatants from different concentrations of cell
suspensions showed that higher concentrations of PBMCs (e.g. 5
million) gave higher specific IgG titers for all antigens in TB
patients at a given time point compared to low cell count (2.5 or 1
million) (Figure 1). This was done in a sub-sample of 30 patients
(smear and culture positive). At any given cell concentration,
antigen-specific antibody titers were highest against BCG followed
by LAM; antibody responses against CFP, TB51A, TB15.3 and
CW were similar.
Using the micro-ALS method with elevated cell concentration
(10610
6 PBMC) in 400 ml culture media, antibody titers were
already high at 24 hrs (mean titers 6 standard deviation,
0.8860.21), and there was only a small increase in antibody
responses after 48 hr (0.9960.19) in patients. Thus, the assay
could be shortened by culturing the PBMC overnight for 16–
18 hours followed by 7 additional hours to run the ELISA assay
(total duration of assay ,30 hours). Supernatant of 10610
6
PBMC from healthy controls showed titers lower than the cut-off
and there was a minimal increase from 24 (0.1760.07) to 48 hrs
(0.2060.09). About 3–4 ml blood was found to be adequate for
this micro-ALS method.
Diagnostic performance of the ALS assay for single
antigens
The intra-assay variation (Coefficient of Variance) was 2.41%.
Repeated freeze-thaw of supernatant interferes with the assay
greatly; thus multiple aliquot of supernatant was collected. Using
new aliquot for the assay gave inter-assay variation of 3.59%,
while use of freeze thawed supernatant gave a variation of 6.89%.
Table 1. Characteristics of patients suspected of having
active pulmonary TB and healthy controls.
Characteristics TB patients
Non-TB
patients
Healthy
controls
Total Number 112 100 25
Cat-1=104 Cat-4=10
Cat-2=8 Cat-9=90
Median age, years 24 (18–70) 26 (18–68) 26 (20–50)
Male: Female 64:48 54:46 15:10
BCG vaccination 41 (36.6%) 42 (42.0%) 25 (100%)
Known history of TB
contact
59 (52.7%) 61 (61.0%) 0
Previous history of TB 11 (9.8%) 7 (7.0%) 0
Occupation
Garments workers 42 (37.5%) 33 (33.0%) -
Daily Laborers 20 (17.9%) 17 (17.0%) -
Housewives 15 (13.4%) 18 (18.0%) -
Students 11 (9.8%) 4 (4.0%) 9 (36.0%)
Service holders 6 (5.4%) 7 (7.0%) 16 (64.0%)
Others 18 (16.0%) 21 (21.0%) -
doi:10.1371/journal.pone.0016425.t001
Figure 1. Antigen specific antibody titers against 6 different
antigens at various cell concentrations in the micro-ALS assay.
Higher concentrations of peripheral blood mononuclear cells produced
higher antigen-specific IgG responses. BCG-specific IgG antibody titers
were highest followed by LAM-specific IgG antibody levels; antibody
responses against CFP, TB51A, TB15.3 and CW were similar.
doi:10.1371/journal.pone.0016425.g001
Validation of the ALS Assay
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16425Receiver-operator characteristic curves were constructed from the
ALS responses to all antigens, comparing TB patients with non-
TB patients. The selection of the best cutoff point was based on the
level at which the accuracy was maximum for each antigen. The
cut-off values for all antigens were very close (0.408 to 0.423)
except for CFP10-ESAT6-A (0.397). The sensitivity, the specific-
ity, positive/negative predictive values and positive/negative
likelihood ratios of the ALS assay was calculated in comparison
to non-TB group (Table 2). The assay using BCG-vaccine as the
antigen showed the highest combination of specificity and
sensitivity (Table 2); the sensitivity was somewhat lower for RD1
antigens TB15.3 and TB51A although the specificity was similar.
The specificity of the fusion protein CFP10-ESAT6-A was about
86% and the sensitivity was lower compared to BCG, LAM,
TB15.3 or TB51A. The negative predictive value was highest for
BCG (91%) followed by LAM and TB51A (90%) and TB15.3
(89%) (Table 2). The positive likelihood ratio (LR+) was good (7.50
and 6.85) for BCG and LAM and suggested conclusive increase in
the likelihood of disease, while for TB51A it was moderate
increase (6.14) in the likelihood of disease. For TB15.3 and
CFP10-ESAT6-A, the LR+ value depicted small increase in the
likelihood of disease. The negative likelihood ratio (LR2) for BCG
and LAM was similar and indicated moderate decrease in the
likelihood of disease (0.1–0.2). The LR- for TB15.3, TB51A and
CFP10-ESAT6-A indicated a small decrease in the likelihood of
disease (0.21–0.5).
When the sensitivity, the specificity, negative/positive predictive
values as well as LR+ and LR- of the ALS assay were calculated in
comparison to healthy controls, all these parameters substantially
increased as expected (data not shown).
Diagnostic performance of the ALS assay increases with
simultaneous detection of multiple antigen-specific
antibodies
The sensitivity and specificity of the ALS assay increased when
antibodies specific against multiple antigens were determined
simultaneously. Thus, a specimen found to be positive for any of
the 7 antigens in the assay was considered to be positive. This led to
a slight increase in sensitivity, specificity and LR+ of the assay and a
decrease inLR2. Thecombination ofall7 antigens gavesensitivity,
specificity and the LR+ of 91%, 88% and 7.58 respectively while a
combination of 3 antigens also showed values close to this, 91%,
86% and 6.50 respectively (Table 2). The best combination
however, was BCG plus LAM that gave the sensitivity, the
specificity and LR+ of 91%, 89% and 8.27 respectively.
Nontuberculous Mycobacterium infection and ALS titers
Wefound4casesofnon-tuberculousMycobacterium(NTM)infections,
one of these patients showed ALS titers higher than the cut-off against
CFP only (0.75), one patient had higher titers against CFP (0.52), CW
(0.44), LAM (0.47), CFP-10-ESAT-6A (0.55) but not against BCG
(0.36). Two patients did not show any response against the 6 antigens.
Non-TB patients with ALS titers higher than the cutoff
There were specimens from twenty one patients belonging to
categories 4 (n=1) and 9 (n=20) whose ALS responses were
higher than the cutoff. Specimens from 9 (43%) of these patients
responded to $6 TB antigens, and a specimen from only one
patient was positive for only one antigen (Table 3). All of these
patients had more than six typical symptoms, 43% had
haemoptysis and 67% had history of contact with active TB.
Table 2. Diagnostic performances of the ALS assay by using single TB specific antigens and simultaneous determination of these
antigens in various combinations.
TB Antigens Sensitivity (95% CI) Specificity (95% CI) PPV NPV LR2 LR+
BCG, n=212 90% (82%–94%) 88% (81%–93%) 87% 91% 0.11 7.50
LAM, n=210 89% (83%–93%) 87% (79%–92%) 85% 90% 0.13 6.85
TB15.3, n=210 85% (77%–91%) 86% (78%–91%) 88% 89% 0.17 6.07
TB51A, n=207 86% (78%–91%) 86% (78%–91%) 88% 90% 0.16 6.14
CFP10-ESAT6-A, n=108 73% (67%–81%) 86% (76%–91%) 86% 88% 0.31 5.21
CW, n=209 86% (77%–91%) 84% (76%–90%) 83% 87% 0.17 5.38
CFP, n=207 82% (74%–88%) 83% (74%–89%) 83% 82% 0.22 4.82
BCG and LAM 91% (84%–95%) 89% (82%–94%) 86% 91% 0.10 8.27
BCG and TB51A 88% (80%–93%) 87% (79%–92%) 88% 91% 0.14 6.77
TB51A and TB15.3 86% (78%–91%) 86% (78%–91%) 86% 88% 0.16 6.14
TB51A, TB15.3 and LAM 87% (79%–92%) 88% (80%–93%) 86% 89% 0.15 7.25
BCG, LAM and TB51A 89% (82%–94%) 87% (79%–92%) 87% 91% 0.13 6.85
BCG, CFP and LAM 91% (83%–95%) 86% (79%–92%) 85% 92% 0.10 6.50
BCG, CFP, LAM and TB51A 89% (81%–94%) 86% (78%–91%) 86% 92% 0.13 6.36
BCG, CFP, LAM, TB51A and TB15.3 89% (81%–94%) 87% (79%–92%) 85% 91% 0.13 6.85
BCG, CFP, LAM, TB51A, TB15.3 and CFP10-ESAT6-A 89% (81%–94%) 86% (79%–92%) 86% 90% 0.13 6.36
BCG, CW, CFP, CFP10-ESAT6-A, LAM, TB51A and TB15.3 91% (83%–95%) 88% (81%–93%) 86% 90% 0.10 7.58
BCG vaccine- glutamate-BCG vaccine for intradermal use, lot 1861, Japan BCG Laboratories, Japan; CFP10-ESAT6-A- fusion protein of Culture filtrate protein-10 and Early
secretory antigenic target-6; TB51A, TB15.3 antigens from RD1 region; CFP- culture filtrate proteins and CW2 cell wall fraction from M. tuberculosis H37Rv and clinical
isolate CSU93; LAM2 lipoarabinomannan of M. tuberculosis H37Rv. ALS titers are given from 48 hrs culture. Receiver-operator characteristic curves were constructed
from the ALS responses to all antigens, comparing TB patients with non-TB patients to select the best cutoff point at which the accuracy was maximum for each
antigen. The cut-off values for all antigens were very close (0.408 to 0.423) except for CFP10-ESAT6-A (0.397). All patients could not be tested for all 7 antigens because
in some cases we did not have enough ALS supernatant.
doi:10.1371/journal.pone.0016425.t002
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Twenty nine of one hundred and twelve culture and/or smear
positive TB patients (categories 1 and 2) had ALS titers lower than
the cut-off (0.42) for one or more antigens. Ten of one hundred
and twelve patients (8.9%) were negative for $6 antigens and 19
(17%) were non-responding to at least one antigen. Ten patients
who were negative for $6 antigens were smear and culture
positive. Nine of these ten patients had presence of more than 6
typical symptoms while one had at least 6 symptoms, six had a
history of contact with active TB, seven had haemoptysis and all
ten had abnormal chest radiograph (Table 3).
Comparison of ALS assay performance between smear
positive and smear negative cases
Specific antibody levels to single antigens LAM and TB51A in
AFB+ TB patients were significantly higherthan AFB2 TB patients
(P,0.02 and P,0.02 respectively). No significant differences were
observed between the two patient groups with respect to other
antigens. When simultaneous detection of all TB antigen-specific
antibodies were considered, the levels of total specific antibodies
were found to be significantly higher in the supernatant of the AFB
smear-positive (AFB+; category 1) TB patients than the AFB smear
negative (AFB2; category 2) TB patients (P,0.001) (Table 4).
The sensitivity of the BCG-specific ALS assay in AFB+ patients
decreased slightly from 91% to 88% in AFB2 patients without
compromising the specificity (88%) (Table 4). The sensitivity of the
LAM-specific ALS assay in AFB+ patients decreased from 92% to
87%in AFB2 patients, the specificity remained unchanged at 87%.
Similar data were obtained fortherest oftheantigens;the specificity
didnotchangebutthesensitivitydecreasedtosomeextent(Table4).
Discussion
The study showed that compared to single antigens, simulta-
neous detection of multiple antigens increased sensitivity, specific-
ity and positive likelihood ratio of the ALS assay in the diagnosis of
Table 3. Profiles of non-TB and category 3 patients with ALS titers higher than the cutoff and TB patients with ALS titers lower
than the cutoff.
Category 4 and 9 patients with ALS titers higher than the cutoff
Positive for
No. of
patients
Previous
TB
History of
TB contact
BCG
given
Abnormal
CXR Typical Symptoms present Haemoptysis
At least 6 more than 6
$6 Antigens 9 (43%) 0 (0%) 8 (89%) 2 (22%) 6 (67%) 0 (0%) 9 (100%) 5 (56%)
#5 Antigens 12 (57%) 0 (0%) 6 (50%) 4 (33%) 11 (92%) 2 (17%) 10(83%) 4 (33%)
Total 21 (100%) 0 (0%) 14 (67%) 9 (28%) 17 (81%) 2 (10%) 14 (90%) 9 (43%)
Positive for Category 3 patients with ALS titers higher than the cutoff
$6 Antigens 3 (33%) 1 (33%) 1 (33%) 2 (67%) 3 (100%) 0 (0%) 2 (67%) 1 (33%)
#5 Antigens 6 (67%) 2 (33%) 3 (50%) 3 (50%) 6 (100%) 1 (17%) 3 (50%) 3 (50%)
Total 9 (100%) 3 (33%) 4 (44%) 5 (55%) 9 (100%) 1 (11%) 5 (55%) 4 (44%)
Negative for Category 1 and 2 TB patients with ALS titers lower than the cutoff
$6 Antigens 10 (34%) 1 (10%) 6 (60%) 5 (50%) 10(100%) 1 (10%) 9 (90%) 7 (70%)
#5 Antigens 19 (66%) 3 (16%) 5 (26%) 9 (47%) 19 (100%) 1 (5%) 18 (95%) 7 (37%)
Total 29 (100%) 4 (14%) 11 (38%) 14 (48%) 29 (100%) 2 (7%) 27 (93%) 14 (48%)
TB2 tuberculosis; BCG2 Bacille Calmette-Gue ´rin vaccine; CXR, X-ray of the chest.
doi:10.1371/journal.pone.0016425.t003
Table 4. Comparison of performance of the ALS assay
between smear positive (C-1) and smear negative (C-2) TB
cases.
TB Antigens
Sensitivity
(95% CI)
Specificity
(95% CI) LR2 LR+
BCG AFB+ 91% (83%–95%) 88% (81%–93%) 0.10 7.58
AFB2 88% (80%–93%) 88% (80%–93%) 0.14 7.33
LAM AFB+ 92% (84%–96%) 87% (80%–93%) 0.09 7.08
AFB2 86% (78%–92%) 87% (79%–92%) 0.16 6.62
TB15.3 AFB+ 87% (79%–92%) 86% (78%–92%) 0.15 6.21
AFB2 71% (67%–82%) 86% (74%–90%) 0.34 5.07
TB51A AFB+ 88% (80%–93%) 86% (78%–92%) 0.14 6.29
AFB2 79% (71%–86%) 86% (77%–91%) 0.24 5.64
CW AFB+ 89% (81%–93%) 84% (77%–90%) 0.13 5.56
AFB2 79% (71%–87%) 84% (75%–89%) 0.25 4.94
CFP AFB+ 88% (80%–93%) 83% (75%–90%) 0.14 5.18
AFB2 76% (69%–84%) 83% (74%–89%) 0.29 4.47
BCG and LAM AFB+ 93% (86%–96%) 89% (82%–94%) 0.08 8.45
AFB2 87% (79%–92%) 89% (81%–94%) 0.15 7.91
All Ag AFB+ 92% (84%–96%) 88% (81%–93%) 0.09 7.67
AFB2 88% (80%–93%) 88% (80%–93%) 0.14 7.33
BCG vaccine- glutamate-BCG vaccine for intradermal use, lot 1861, Japan BCG
Laboratories, Japan; CFP10-ESAT6-A- fusion protein of Culture filtrate protein-10
and Early secretory antigenic target-6; TB51A, TB15.3 antigens from RD1 region;
CFP2 culture filtrate proteins and CW2 cell wall fraction from M. tuberculosis
H37Rv and clinical isolate CSU93; LAM2 lipoarabinomannan of M. tuberculosis
H37Rv. AFB+, sputum AFB smear positive; AFB2, sputum AFB smear negative.
ALS titers are given from 48 hrs culture. The cut-off values for all antigens were
very close (0.408 to 0.423) except for CFP10-ESAT6-A (0.397).
doi:10.1371/journal.pone.0016425.t004
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gave highest combination of sensitivity and specificity. The micro-
ALS method shortened the duration of the assay and increased the
possibility of detecting borderline cases.
We have earlier applied the ALS assay in diagnosing active TB
disease in adults, in their household contacts and in pediatric
patients [10,11,12] where BCG vaccine was used as the coating
antigen for ELISA. In this study multiple antigens were used to
identify suitable Mycobacterium tuberculosis specific antigens that
might be better compared to the BCG vaccine. The expression of
proteins encoded on the region of difference (RD-1) domain of the
genome (e.g. ESAT-6, CFP-10, TB15.3 and TB51A) is known to
be absent in BCG substrains and many environmental mycobac-
teria [13,14,15]. We found that BCG vaccine gave the highest
accuracy and precision compared to other single antigens. The
RD1 antigens TB15.3, TB51A and fusion protein CFP10-ESAT6-
A had high specificity but the sensitivity was lower than for BCG.
BCG vaccine strain being a large molecule consisting of diverse
types of antigens, including lipids and proteins may have provided
a broader range of antigenic epitopes for capturing antibodies
from circulating plasma cells [14]. Again, simultaneous determi-
nation of multiple antigen specific antibodies also increased the
sensitivity and specificity of the ALS assay and could enhance the
possibility of case detection. This was in agreement with the recent
observations of other researchers showing combination of antigens
to be more effective in serological assays for diagnosis of TB with
increased sensitivity and specificity compared to single antigens
[16,17]. Interestingly, the accuracy of the ALS method using
simultaneous determination of BCG and LAM responses was
higher than the combination of 6 antigens. The specificity of the
ALS assay was substantially higher when healthy controls were
considered instead of non-TB controls (data not shown).
The use of higher PBMC concentration in a smaller volume of
culture media in the micro-ALS method allowed for increased
concentration of released antibodies in the supernatant thus
permitting a shorter period of cell culture and increased detection.
The micro-ALS method also had the potential to identify
borderline TB cases that might otherwise be missed due to lower
production of specific antibodies by low cell numbers. Severe to
moderately ill TB patients exhibit significantly lower cell count per
ml of blood compared to healthy subjects (personal observation).
More importantly pediatric patients produce lower amounts of
antibodies in serum compared to adults [18,19,20] and have a
greater risk of being ruled out for TB in serological assays. In
elderly and immunocompromised patients (e.g. having HIV and
renal diseases) with TB as a co-infection, definitive diagnosis
becomes challenging due to nonspecific clinical and radiological
signs. Serological and interferon gamma release assays (IGRAs) in
these patients show suboptimal sensitivity [21,22,23,24,25] and
cannot differentiate between disease and infection. Nucleic acid
amplification tests (NAAT) methods are also less sensitive in
immunocompromised patients and in paucibacillary TB [26]. The
micro-ALS method thus appears promising and may have the
potential to be more sensitive in diagnosing TB in immunosup-
pressed patients.
The positive ALS results for several of the antigens in several
patients who had negative smears and cultures, but symptoms
consistent with TB suggests that the ALS assay may detect cases of
active TB which are not being identified using standard methods.
Among the patients in category 4 and 9, the fact that 43% of these
patients being positive for $6 antigens and 90% for at least 3
antigens suggest that these were true TB cases with typical
symptoms in whom TB disease was initially suspected and
subsequently ruled out due to negative culture and indeterminate
CXR. Although mycobacterial culture is considered the gold
standard in TB diagnosis sputum culture is not a very sensitive
method, all pulmonary TB cases do not always become sputum
culture positive. Thus, possibility of some degree of misclassifica-
tion of disease remains. Further evaluation of such patients is
needed to determine if these patients represent false positive ALS
results or false negative culture results.
Among the culture confirmed TB cases, 10 patients were ALS
negative for all antigens while the rest responded to at least 1 or
more antigens. These false negative findings suggest that further
modifications of the ALS assay are needed to improve sensitivity.
AFB+ patients had significantly higher levels of antigen-specific
IgG titers compared to AFB2 patients which has also been seen
with serological methods [17] and might be attributed to bacterial
burden, levels of antigens, and the stage of disease [7,9].
There are a number of limitations of the study. ESAT-6 and
CFP10 antigens are absent from BCG strains and from most
environmental mycobacteria, with the exception of M. kansasii, M.
szulgai, M. marinum and M. gordonae [27]. Our findings indicate that
patients with the above NTM infections may be misdiagnosed as
M. tuberculosis cases by the ALS assay depending on the selection of
antigens used and thereby may affect the diagnostic specificity to
some extent. The classification of Category 9 patients as non-TB
who had high ALS titers and whose conditions worsen or
remained unchanged after 2 months of anti-TB therapy was
doubtful. It may be possible that some of these patients were
infected with MDR TB that were paucibacillary in nature,
consequently in absence of a positive sputum culture the diagnosis
could not be confirmed. The Mantoux Test showed 8 healthy
subjects to have latent TB, none of whom showed ALS-IgG titers
higher than the cut-off (against BCG) suggesting that ALS assay
does not detect latent TB. However, we did not apply Quantiferon
method as a confirmatory/complimentary test for exclusion of
latent TB in them.
In conclusion, the findings show that simultaneous determina-
tion of at least two antigens, LAM and BCG and application of the
micro-ALS method improves diagnostic accuracy of the ALS assay
and reduces the assay time considerably. Together with consid-
eration of key clinical characteristics, it can support rapid detection
of TB cases, to identify false negative cases and compliment other
techniques e.g. IGRA in differentiating latent TB from active TB
infection and enable correct judgment on appropriate anti-TB
treatment. Further work is ongoing to evaluate the performance of
ALS assay in the diagnosis of TB in HIV infected patients and in
extra pulmonary TB.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Review Committee of
the International Center for Diarrheal Diseases Research,
Bangladesh (ICDDR,B). All patients gave their written informed
consent.
Study subjects and sampling
Adult patients with suspected pulmonary TB who attended the
National Institute of Diseases of the Chest and Hospital (NIDCH)
in Dhaka, Bangladesh, were prospectively studied. This study was
part of the WHO/TDR Tuberculosis Specimen Bank activity [28]
in which blood, sputum/saliva and urine specimens were collected
from well-characterized TB patients. All specimens were collected
and processed using a standardized protocol provided by the
WHO and was accompanied by complete clinical information,
including the HIV status. HIV testing was done by standard
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presentation, chest radiograph examination, and sputum smear
and culture positivity as described in case definition. The typical
symptoms included persistent cough ($ three weeks), fever,
malaise, recent weight loss, night sweats, contact with active case
(intimate or household contact), hemoptysis, chest pain– pleuritic
or otherwise and loss of appetite. Healthy laboratory personnel
with no known exposure to M. tuberculosis were selected as healthy
control subjects. These healthy subjects underwent Mantoux test
after blood was collected for the ALS assay, since performance of
Mantoux test within the past 30 days influences the ALS test (data
not shown). The study was approved by the ethical review
committee of International Centre for Diarrhoeal Disease
Research, Bangladesh (ICDDR,B). Signed informed consent was
obtained from each study subject according to the guidelines of the
Institutional Review Board of the Centre.
Case definitions
Patients with two sputum smears positive for acid-fast bacilli
(AFB) and at least 1 culture positive on solid media are considered
Category 1 TB patients. Category 2 is a patient with 2 negative
smears and at least 1 culture positive and abnormal chest x-ray
(CXR). Category 3 is a patient with 2 negative smears and
cultures, clinical symptoms, radiographic abnormalities consistent
with active PTB, no response to broad spectrum non-TB
antibiotics with clinical and radiographic improvement after 3
months of a full course of anti-TB chemotherapy, a decision taken
by the clinician. Category 4 patients have 2 negative smears and
cultures on initial assessment; CXR is irrelevant and are still
negative in smear and culture at 2–3 months follow-up; Category
4 is thus non-TB. Category 9 patients are indeterminate cases with
a combination of results not matching categories 1–4 and in whom
disease diagnosis may or may not be confirmed.
Specimens
From each patient sputum samples were collected twice on
consecutive days for acid-fast bacilli (AFB) staining. For isolat-
ing Mycobacterium spp., sputum samples were cultured on solid
(Lowenstein-Jensen slants) (L–J) as well as in liquid (manual
MGIT, Becton Dickenson, USA) systems following standard
procedures. Inoculated L–J slants were weekly checked for
characteristic growth of mycobacterial colonies until 8 weeks.
Sputum was considered negative when there is no characteristic
growth of Mycobacterium on L–J slant within 8
th weeks. Similarly,
inoculated MGIT tubes were also checked for positive fluores-
cence weekly until 8
th weeks. Part of palette (from 500 microliter
broth) of fluorescence positive MGIT tube was stained for AFB.
When positive, the remaining part of the pellet was inoculated on
L–J slant for isolation of Mycobacterium spp. A culture was
confirmed M. tuberculosis based on three biochemical tests: niacin
(positive), nitrate (positive) and P-nitro benzoic acid (sensitive). Any
deviation from these tests was considered as non-tuberculous
Mycobacterium [29]. Positive cultures were inoculated for drug
sensitivity testing. Blood samples were collected from each patient
at enrollment and from healthy subjects for the ALS assay.
The ALS assay
Peripheral blood mononuclear cells (PBMCs) were separated
from blood on Ficoll-Paque by differential centrifugation and
suspended in 24-well tissue culture plates (Costar, Cambridge, MA)
in tissue culture medium. PBMCs at a cell concentration of
(1610
6 cells/ml) were incubated at 37uC with 5% CO2 and culture
supernatants were collected after 48 hrs and stored at 270uC until
used for measurement of immunoglobulin G (IgG) titers. Polysty-
rene microtiter plates (MaxiSorp, Nunc) were coated with TB
specific antigens (described below) in carbonate buffer (0.1 M
sodium bicarbonate and 5 mM magnesium chloride [pH 9.8]) and
incubated overnight at 4uC. After washing, the plates were
incubated first with 10% fetal bovine serum in phosphate-buffered
saline (pH 7.2) andthen with lymphocyte supernatants,eachfor2 h
at 37uC, with intermittent washing. Horseradish peroxidase-
conjugated rabbit anti-human IgG was added and incubated for
2 h at room temperature. Plates were developed with the substrate
O-phenylenediamine and the optical density (OD) was measured at
492 nm. Pooled sera from M. tuberculosis culture-positive patients
were used as positive controls (OD, .1.0). Negative control was the
antigen coated wells with conjugate and substrate. Antigen-specific
responseswereexpressedasrelative titers,which weredefined asthe
optical density of the test specimen minus the optical density of the
control wells. Each specimen was run in duplicates in the ALS assay
and the mean was used to calculate the results.
In sub-samples with high blood volume (n=30), cells were
incubated and supernatant collected as above to determine the
concentration of antibodies in variable cell concentrations (1610
6,
2.5610
6 and 5610
6 cells/ml) against the 6 different TB antigens
(Figure 1). In another subsample (n=30), 5610
6 cells/well and
10610
6 cells/well were added in smaller volume of culture media
(400 microliters/well), incubated for 24 and 48 hours, and culture
supernatants collected as above for determination of antibody
concentrations. Hereafter this method using low volume of culture
media was called the micro-ALS method. The clinical information
or the diagnostic report of the patients was not blinded; however
laboratory personnel were not aware of the diagnosis during the
performance of the ALS test.
Antigens for coating microtiter plates
The BCG vaccine (freeze-dried, glutamate-BCG vaccine for
intradermal use; lot 1861; Japan BCG Laboratories, Japan) used in
the Extended Program on Immunization for the vaccination of
infants and children in Bangladesh was obtained. CFP10-ESAT6-
A, TB51A, TB15.3 were obtained from State Serum Institute,
Copenhagen, Denmark; CFP (culture filtrate proteins) and CW
(cell wall fraction) from M. tuberculosis H37Rv and clinical isolate
CSU93, LAM (lipoarabinomannan) of M. tuberculosis H37Rv was
obtained from Colorado State University, CO, USA (NIH, NIAID
Contract NO1 AI-75320). To coat microtiter plates, antigens were
used in the following concentrations: BCG vaccine (1 mg/well);
LAM (0.01 mg/well); CFP (0.05 mg/well); TB51A (0.05 mg/well);
TB15.3 (0.1 mg/well); CW (0.05 mg/well) and fusion protein
CFP10-ESAT6-A (1 mg/well). TB51A, TB15.3, CFP-10 and
ESAT-6 are proteins that are encoded on the region of difference
(RD-1) domain of the Mycobacterium tuberculosis genome. Microtiter
plates were coated with the different antigens separately/singly
and antigen cocktail was not used in any ELISA assay.
Statistical analysis
Statistical analyses were performed by using PASW (version 17;
SPSS Inc., Chicago, IL). Receiver operator characteristic (ROC)
analysis was performed to evaluate sensitivity and specificity of
different TB antigen specific IgG titers in the ALS assay based on
the cutoff of positivity. Positive and negative predictive values,
positive and negative likelihood ratio were also determined.
Student’s t test was applied when comparing between two groups.
A P value ,0.05 was considered statistically significant.
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